NICE u-turn sees Akcea’s Waylivra win NHS funding
The drug is the first and only therapy for the ultra rare condition Familial Chylomicronaemia Syndrome (FCS)
Read Moreby Selina McKee | Sep 18, 2020 | News | 0
The drug is the first and only therapy for the ultra rare condition Familial Chylomicronaemia Syndrome (FCS)
Read Moreby Anna Smith | May 24, 2019 | News | 0
The drug should be available for routine use within 90 days for patients in England.
Read Moreby Anna Smith | Apr 17, 2019 | News | 0
The decision will allow patients in England with the rare, inherited, severely debilitating and fatal disease to access the treatment on the NHS.
Read Moreby Anna Smith | Feb 26, 2019 | News | 0
Novartis has announced that it is exercising its option to license the rights to develop and commercialise Akcea’s TQJ230.
Read Moreby Selina McKee | Dec 12, 2018 | News | 0
The National Institute for Health and Care Excellence has issued draft guidelines rejecting NHS funding for two therapies that treat the rare inherited condition hereditary transthyretin-related amyliodsis (hATTR).
Read Moreby Selina McKee | Oct 8, 2018 | News | 0
Akcea and Ionis’ Tegsedi has won US approval for patients with hereditary transthyretin amyloidosis (hATTR), a rare disease causing build up of amyloid in the peripheral nervous system and multiple organs.
Read Moreby Selina McKee | Aug 28, 2018 | News | 0
US regulators have rejected Akcea/Ionis’ application to market Waylivra for the ultra-rare rare lipid disorder familial chylomicronemia syndrome (FCS).
Read Moreby Selina McKee | Jul 17, 2018 | News | 0
European regulators have approved Akcea and Ionis’ Tegsedi for patients with hereditary transthyretin amyloidosis (hATTR), a rare disease causing build up of amyloid in the peripheral nervous system and multiple organs.
Read Moreby Selina McKee | May 11, 2018 | News | 0
Akcea Therapeutics’ volanesorsen has taken a step closer to becoming the first therapy on the US market for the ultra-rare rare lipid disorder familial chylomicronemia syndrome (FCS).
Read Moreby Selina McKee | Oct 10, 2017 | News | 0
Akcea Therapeutics’s volanesorsen has been granted a Promising Innovative Medicine designation by the Medicines and Healthcare products Regulatory Agency for the treatment of familial chylomicronaemia syndrome, a rare genetic lipid disorder.
Read Moreby Selina McKee | Jan 6, 2017 | News | 0
Novartis has signed an exclusive option agreement with Ionis and affiliate Akcea to license two investigational therapies that could significantly reduce cardiovascular risk in patients living with elevated levels of lipoproteins Lp(a) and ApoCIII.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
